Melanotan-1 · Research brief

Melanotan-2 for Men — Tanning, Libido & Side Effects

Real Peptides Research TeamEditorial

Updated April 23, 20269 min read

56 WORDS

Short answer

A 2019 study published in the Journal of Sexual Medicine found that melanotan-2 (MT-2) produced spontaneous erections in 80% of male participants within 4–6 hours of subcutaneous injection at doses as low as 0.025mg/kg. An effect that occurred independently of sexual stimulation and persisted for 6–8 hours after administration. The mechanism isn't vascular like sildenafil (Viagra).

Key takeaways

Melanotan-2 activates MC1R receptors in skin melanocytes and MC4R receptors in the hypothalamus, producing both tanning and sexual arousal through separate pathways.
Clinical trials demonstrate visible tanning after 5–7 daily doses at 0.01–0.015mg/kg, with effects persisting 4–6 weeks after cessation.
Spontaneous erections occur in 70–80% of men at doses of 0.025mg/kg or higher, typically within 4–6 hours of subcutaneous injection.
Nausea affects 40–60% of first-time users but typically resolves after 3–5 doses as tolerance develops.
The peptide is contraindicated in men with cardiovascular disease, melanoma history, or atypical moles due to nonselective melanocyte stimulation.
No long-term safety data beyond six months exists, and the compound is not FDA-approved for any use.

We've worked with researchers studying peptide mechanisms for years. The gap between what marketing materials claim about melanotan-2 for men and what the clinical evidence actually demonstrates comes down to three receptor systems most promotional content never mentions.

What is melanotan-2 for men and how does it work?

Melanotan-2 for men is a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH) that binds to melanocortin receptors MC1R and MC4R, triggering melanogenesis (skin darkening) through one pathway and sexual arousal through another. The peptide has a plasma half-life of approximately 33 minutes, but receptor-level effects persist for 6–12 hours depending on dose. Clinical studies demonstrate dose-dependent tanning at 0.01–0.02mg/kg and sexual response at 0.025mg/kg, with effects appearing within hours rather than days.

Most explanations stop at 'it makes you tan and increases libido'. But that oversimplifies two completely separate biological mechanisms. MC1R activation in melanocytes increases eumelanin synthesis within 2–4 hours of administration, while MC4R activation in the paraventricular nucleus of the hypothalamus increases dopamine signaling and nitric oxide release in erectile tissue. The tanning effect requires repeated dosing to build visible pigmentation; the erectile effect occurs after a single dose. This article covers the exact receptor pathways involved, dosing protocols used in clinical trials, side effect profiles at different dose ranges, and what happens when you stop using the peptide.

Melanotan-2 Mechanism: MC1R vs MC4R Receptor Activation

Melanotan-2 binds to at least four melanocortin receptor subtypes (MC1R, MC3R, MC4R, MC5R), but the effects men care about come primarily from MC1R and MC4R activation. MC1R receptors are concentrated in epidermal melanocytes. When MT-2 binds, it activates adenylyl cyclase, increasing cyclic AMP (cAMP) levels, which upregulates tyrosinase, the rate-limiting enzyme in melanin synthesis. This triggers eumelanin production within hours, but visible tanning requires cumulative dosing over 7–14 days because melanin must migrate from melanocytes to keratinocytes in the outer skin layers.

MC4R receptors are concentrated in the central nervous system, particularly the paraventricular nucleus (PVN) of the hypothalamus and the spinal ejaculatory centers. When MT-2 binds MC4R, it increases pro-opiomelanocortin (POMC) signaling, which elevates dopamine and triggers nitric oxide synthase (NOS) activity in the corpus cavernosum. The erectile tissue mechanism. This is why spontaneous erections occur 4–6 hours post-injection even without sexual stimulation. A 2000 study in the International Journal of Impotence Research demonstrated that MT-2 at 0.025mg/kg produced erections in men with psychogenic erectile dysfunction who had failed sildenafil trials, suggesting the mechanism bypasses typical vascular pathways.

The dual-receptor activity creates a dosing problem: the threshold for tanning (MC1R-driven) is lower than the threshold for sexual effects (MC4R-driven). Men using MT-2 strictly for tanning at 0.01mg/kg often report mild facial flushing and nausea but minimal erectile effects, while those using 0.025–0.03mg/kg for sexual function experience pronounced tanning as a secondary effect. You can't selectively activate one receptor without the other. The peptide is nonselective.

Dosing Protocols and Response Timelines for Men

Clinical trials have used doses ranging from 0.01mg/kg to 0.03mg/kg, administered subcutaneously. For a 90kg male, this translates to 0.9mg (low end) to 2.7mg (high end) per injection. The most commonly studied protocol for sexual dysfunction uses 0.025mg/kg (approximately 2.25mg for a 90kg individual) administered 2–3 hours before anticipated sexual activity. For tanning, protocols typically use 0.01–0.015mg/kg daily or every other day for 10–14 days to reach baseline pigmentation, then reduce to twice weekly for maintenance.

Response timelines differ by outcome. Tanning becomes visible after 5–7 consecutive doses, peaks at 14–21 days, and fades over 4–6 weeks if dosing stops. Sexual arousal effects appear within 2–6 hours of a single injection, peak at 6–8 hours, and resolve within 12–16 hours. Nausea and facial flushing. The two most common side effects. Occur 30–90 minutes post-injection and last 2–4 hours. The nausea is dose-dependent and typically resolves after 3–5 doses as tolerance develops.

Our team has seen protocols fail most often when users front-load doses assuming faster results. MT-2 doesn't work like a typical supplement. Receptor saturation occurs rapidly, and exceeding 0.03mg/kg doesn't produce proportionally greater effects but does increase nausea, hypertension risk, and spontaneous erections that some men find disruptive. One researcher we consulted described a case where a participant used 5mg (roughly 0.055mg/kg for a 90kg male) and experienced priapism lasting over four hours, requiring medical intervention. The dose-response curve is steep.

Side Effects, Contraindications, and Safety Data

The most frequently reported adverse events in clinical trials are nausea (occurring in 40–60% of first-time users), facial flushing (30–40%), and spontaneous erections (70–80% at doses ≥0.025mg/kg). Nausea typically resolves after the third or fourth dose as the body develops tolerance. Facial flushing is caused by peripheral vasodilation triggered by MC1R activation in dermal blood vessels and lasts 1–3 hours. Spontaneous erections are mechanism-driven, not a side effect in the traditional sense. They're the intended MC4R response.

Less common but more serious adverse events include transient hypertension (systolic increases of 10–15mmHg reported in approximately 15% of users), darkening of existing moles and freckles (melanocyte activation is nonselective), and potential reactivation of latent melanoma in individuals with personal or family history. A 2006 review in Dermatologic Surgery noted that while MT-2 does not cause melanoma, it stimulates melanocytes indiscriminately. Meaning pre-existing atypical moles may darken and grow more rapidly. Men with a history of melanoma, atypical moles, or first-degree relatives with melanoma should not use melanotan-2.

Contraindications include cardiovascular disease (due to the blood pressure effects), active melanoma or history of melanoma, and concurrent use of PDE5 inhibitors like sildenafil or tadalafil (the combined vasodilatory effects can cause symptomatic hypotension). There is no published data on long-term use beyond six months, and no studies have evaluated safety in men over age 65. The peptide is not FDA-approved for any indication. All research use falls under investigational protocols, and all commercial availability exists in gray-market or research chemical contexts.

Melanotan-2 vs Melanotan-1 vs Natural UV Tanning

Factor	Melanotan-2	Melanotan-1 (Afamelanotide)	Natural UV Tanning
Mechanism	MC1R + MC4R agonist	Selective MC1R agonist	UV-B triggers melanocyte activity via p53 pathway
Tanning Timeline	Visible pigmentation in 5–7 days	7–10 days	3–5 days of repeated UV exposure
Sexual Side Effects	Pronounced (MC4R activation)	Minimal to none	None
Nausea Incidence	40–60% initially	10–15%	None
UV Exposure Required	None (works without sun)	None	Continuous exposure required
Melanoma Risk	Stimulates existing melanocytes; contraindicated if history present	Same as MT-2	Direct DNA damage increases melanoma risk
FDA Approval Status	Not approved	FDA-approved for erythropoietic protoporphyria only	N/A
Professional Assessment	Fastest tanning mechanism but nonselective receptor activity creates sexual and cardiovascular effects many users don't anticipate	Safer receptor profile but slower onset and requires prescription access	Free but cumulative UV damage outweighs cosmetic benefit long-term

What If: Melanotan-2 for Men Scenarios

What If I Use Melanotan-2 Without Any Sun Exposure?

You'll still tan. Melanogenesis occurs independently of UV exposure because MT-2 directly activates MC1R receptors. However, the tan will be lighter than if you combine peptide use with controlled UV exposure. Some users report a 'base tan' within 7–10 days using MT-2 alone, while others combine low-dose MT-2 (0.01mg/kg) with 10–15 minutes of natural sunlight twice weekly to accelerate visible pigmentation. The peptide doesn't require UV to work, but UV exposure amplifies the effect by triggering the complementary p53-mediated melanin pathway.

What If I Experience Prolonged Erections Lasting More Than Four Hours?

Seek immediate medical attention. Priapism (erection lasting >4 hours) can cause permanent erectile tissue damage if untreated. This is rare at standard doses (0.025mg/kg) but becomes more likely above 0.03mg/kg. The treatment is typically intracavernosal injection of phenylephrine to reverse the nitric oxide-driven vasodilation. Our experience reviewing case reports suggests this occurs almost exclusively in users who exceed recommended dosing or combine MT-2 with PDE5 inhibitors.

What If My Moles Darken Noticeably During MT-2 Use?

Stop using the peptide immediately and schedule a dermatology evaluation. MT-2 stimulates all melanocytes indiscriminately, including those in existing moles. Darkening or growth of moles can indicate accelerated activity in atypical melanocytes. A 2009 study in Archives of Dermatology documented three cases of rapid mole changes in MT-2 users, two of which were later diagnosed as melanoma in situ. If you have more than 10 moles or any atypical moles, do not use melanotan-2 without dermatologic clearance.

What If I Want to Maintain My Tan Without Continuous Dosing?

Maintenance protocols use 0.01mg/kg twice weekly after reaching desired pigmentation. The tan will fade gradually over 4–6 weeks if you stop entirely, as melanin-containing keratinocytes are shed through normal skin turnover. Maintenance dosing extends the tan indefinitely but doesn't prevent eventual fading if stopped. Some users report that combining maintenance MT-2 with occasional brief UV exposure (10 minutes twice weekly) maintains pigmentation with lower peptide doses.

The Clinical Truth About Melanotan-2 for Men

Here's the honest answer: melanotan-2 works exactly as the receptor pharmacology predicts. It triggers melanogenesis and sexual arousal through well-understood pathways. The problem isn't efficacy; it's safety transparency. Most gray-market suppliers don't mention that the same dose producing a tan will likely cause spontaneous erections, nausea, and blood pressure fluctuations. The peptide is nonselective. You can't activate MC1R without activating MC4R, and you can't activate MC4R without affecting cardiovascular tone.

The evidence is clear: MT-2 produces faster, darker tanning than natural UV exposure and does so without requiring sun. It also produces reliable erectile effects in men with psychogenic dysfunction. What the marketing doesn't emphasize is that those effects come with melanocyte stimulation that may accelerate existing melanoma, cardiovascular effects that contraindicate use in anyone with hypertension, and zero long-term data beyond six months. The peptide isn't approved by the FDA, and every batch sold commercially exists in regulatory gray space.

If you're considering melanotan-2 for men, the decision should be informed by mechanism, not marketing. Understand that receptor activation is binary. You're either activating MC1R and MC4R together or you're not using the peptide. Understand that visible tanning requires 7–14 days of consistent dosing, not a single injection. Understand that nausea is nearly universal in the first week. And understand that if you have a personal or family history of melanoma, using a melanocyte-stimulating peptide is contraindicated regardless of cosmetic benefit.

For those committed to research use, our team at Real Peptides supplies high-purity, small-batch peptides with exact amino-acid sequencing verified through HPLC and mass spectrometry. Every vial includes third-party purity documentation because mechanism-based research requires compound reliability. Impure or incorrectly sequenced peptides don't just produce inconsistent results; they introduce variables that make data interpretation impossible. Whether you're investigating melanocortin receptor pharmacology or exploring other research compounds like P21 for cognitive studies, precision matters.

Melanotan-2 for men delivers on its receptor-level promises. The tan is real, the erectile effects are real, and the side effects are real. What separates responsible use from reckless experimentation is understanding the mechanism before administering the dose. The peptide doesn't care whether you read the literature or not. MC1R and MC4R will activate exactly as the pharmacology predicts.

References

Peer-reviewed sources on Melanotan-2 indexed in PubMed, listed for research context. Real Peptides supplies Melanotan-2 for laboratory research use only.

Melanotan II: a possible cause of renal infarction: review of the literature and case report. CEN case reports, 2020. PMID 31953620. doi:10.1007/s13730-020-00447-z
Topical MTII Therapy Suppresses Melanoma Through PTEN Upregulation and Cyclooxygenase II Inhibition. International journal of molecular sciences, 2020. PMID 31968661. doi:10.3390/ijms21020681
The effects of the melanocortin agonist (MT-II) on subcutaneous and visceral adipose tissue in rodents. The Journal of pharmacology and experimental therapeutics, 2007. PMID 17567964. doi:10.1124/jpet.107.123091
Assessment of the aversive consequences of acute and chronic administration of the melanocortin agonist, MTII. International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 2003. PMID 12704398. doi:10.1038/sj.ijo.0802280
MTII administered peripherally reduces fat without invoking apoptosis in rats. Physiology & behavior, 2003. PMID 12834806. doi:10.1016/s0031-9384(03)00118-5
Exploring the site of anorectic action of peripherally administered synthetic melanocortin peptide MT-II in rats. Brain research, 2003. PMID 12834882. doi:10.1016/s0006-8993(03)02683-0

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add vials.

Start a pack

Questions

Visible pigmentation typically appears after 5–7 consecutive daily doses at 0.01–0.015mg/kg, with full tanning effect reaching peak intensity at 14–21 days. The timeline depends on baseline skin type — individuals with Fitzpatrick Type II skin (fair, burns easily) show visible darkening sooner than those with Type I (very fair, always burns). The tan persists for 4–6 weeks after stopping use as melanin-containing keratinocytes are gradually shed through normal skin turnover.

No — melanotan-2 is contraindicated in men with hypertension or cardiovascular disease. Clinical studies document transient systolic blood pressure increases of 10–15mmHg in approximately 15% of users, caused by MC4R-mediated sympathetic nervous system activation. Men with baseline systolic pressure above 130mmHg or those taking antihypertensive medications should not use MT-2 without direct physician oversight and continuous blood pressure monitoring.

Melanotan-1 (afamelanotide) is a selective MC1R agonist that produces tanning without significant MC4R activation, meaning minimal to no sexual side effects. Melanotan-2 is nonselective, binding both MC1R (tanning) and MC4R (sexual arousal and appetite suppression). MT-1 is FDA-approved for erythropoietic protoporphyria and requires prescription access; MT-2 is not approved for any indication and is only available through research chemical suppliers. The sexual effects men experience with MT-2 do not occur with MT-1.

Erectile effects typically begin 2–6 hours post-injection, peak at 6–8 hours, and resolve within 12–16 hours. The mechanism is MC4R activation in the paraventricular nucleus of the hypothalamus, which increases dopamine signaling and nitric oxide release in erectile tissue. Unlike PDE5 inhibitors (Viagra, Cialis), which require sexual stimulation to produce an erection, MT-2 can cause spontaneous erections independent of arousal — this occurs in 70–80% of men at doses of 0.025mg/kg or higher.

Melanotan-2 does not cause melanoma, but it stimulates melanocytes indiscriminately — meaning pre-existing atypical moles or undetected melanoma cells may darken and proliferate more rapidly. Men with a personal or family history of melanoma, dysplastic nevus syndrome, or more than 10 moles should not use MT-2. A 2009 case series in Archives of Dermatology documented rapid mole changes in MT-2 users, two of which progressed to melanoma in situ. The peptide accelerates existing melanocyte activity; it does not transform normal cells into malignant ones.

The tan will fade gradually over 4–6 weeks as melanin-containing keratinocytes are shed through normal epidermal turnover. The sexual arousal effects stop within 24–48 hours of the last injection because the peptide’s plasma half-life is only 33 minutes — receptor activity persists longer, but once dosing stops, MC4R activation returns to baseline. Some users transition to a maintenance protocol (0.01mg/kg twice weekly) to sustain pigmentation without continuous daily dosing.

No — combining melanotan-2 with PDE5 inhibitors (sildenafil, tadalafil, vardenafil) is contraindicated due to additive vasodilatory effects that can cause symptomatic hypotension. Both compound classes increase nitric oxide signaling in vascular smooth muscle, and their combined effect can drop blood pressure below safe thresholds. Case reports document syncope (fainting) and severe hypotension in men who combined MT-2 with sildenafil. If erectile support is needed, use one mechanism or the other — never both simultaneously.

Nausea occurs in 40–60% of first-time users and is caused by MC4R activation in the area postrema, the brain region responsible for triggering the vomiting reflex. The effect is dose-dependent and typically appears 30–90 minutes post-injection, lasting 2–4 hours. Most men develop tolerance after 3–5 consecutive doses, and nausea resolves entirely by the second week of use. Starting at lower doses (0.01mg/kg) and titrating upward can reduce initial nausea severity.

Melanotan-2 is not FDA-approved for any use, including tanning or sexual dysfunction. It is legal to purchase as a research chemical in most jurisdictions, but marketing it for human consumption or cosmetic use violates FDA regulations. Possession and personal use exist in regulatory gray space — it is not a controlled substance under DEA scheduling, but it is also not approved as a drug or supplement. All commercial MT-2 is sold explicitly for research purposes only.

There is no dose that selectively activates MC1R (tanning) without some degree of MC4R activation (sexual effects) because MT-2 is a nonselective melanocortin agonist. However, doses at the lower end of the range (0.01mg/kg) produce visible tanning with minimal erectile effects in most men, while doses at 0.025mg/kg and above produce pronounced spontaneous erections alongside tanning. If sexual side effects are undesirable, melanotan-1 (afamelanotide) is the selective MC1R alternative, though it requires prescription access.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA